被困在“火烧火燎”疼痛里的15年

Core Viewpoint - The article highlights the struggles of a Fabry disease patient in Sichuan, China, and the potential breakthrough of a gene therapy drug, ZS805, which may offer a long-term solution for patients suffering from this rare disease [3][9]. Group 1: Patient Experience - Fabry disease is characterized by severe pain, kidney damage, and heart complications, significantly impacting the quality of life of patients [3][5]. - The patient, referred to as A Fei, experienced debilitating pain from the age of 10 and faced a long diagnostic journey, finally receiving a diagnosis at 18, only to be told there was no available treatment [5][6]. - The financial burden of treatment for Fabry disease can exceed 1 million yuan annually, making it unaffordable for many patients [6][8]. Group 2: Treatment Developments - In 2018, the Chinese government included Fabry disease in its list of rare diseases, leading to the approval of enzyme replacement therapy (ERT) in 2022, which has provided some relief to patients [6][8]. - The introduction of the gene therapy drug ZS805, currently in clinical trials, aims to provide a one-time treatment that could potentially eliminate the need for ongoing therapy [10][11]. - ZS805 has received clinical trial approvals from both the Chinese National Medical Products Administration and the U.S. FDA, marking a significant advancement in the treatment landscape for rare diseases [11][12]. Group 3: Industry Challenges - The development of rare disease drugs like ZS805 requires substantial financial investment and faces challenges such as low success rates and limited market demand [12]. - The potential pricing of ZS805 could reach over 1 million yuan annually, raising concerns about affordability for patients while also posing a challenge for companies to recoup development costs [12]. - Collaboration among government, enterprises, and patient communities is essential to address the complexities of rare disease treatment and ensure sustainable solutions [12].